On the Need for Landmark Analysis or Time-dependent Covariates.
作者信息
Zabor Emily C, Assel Melissa
机构信息
Department of Quantitative Health Sciences, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
J Urol. 2023 Jun;209(6):1060-1062. doi: 10.1097/JU.0000000000003459. Epub 2023 Apr 11.
Abstract
摘要
相似文献
1
On the Need for Landmark Analysis or Time-dependent Covariates.论地标分析或时间依存性协变量的必要性。
J Urol. 2023 Jun;209(6):1060-1062. doi: 10.1097/JU.0000000000003459. Epub 2023 Apr 11.
2
Landmark cure rate models with time-dependent covariates.具有时间依存性协变量的标志性治愈率模型。
Stat Methods Med Res. 2017 Oct;26(5):2042-2054. doi: 10.1177/0962280217708681. Epub 2017 Jun 19.
3
Applications of statistics to medical science, IV survival analysis.统计学在医学中的应用，IV生存分析。
J Nippon Med Sch. 2012;79(3):176-81. doi: 10.1272/jnms.79.176.
4
Survival analysis in clinical trials: old tools or new techniques.临床试验中的生存分析：旧工具还是新技术
Surg Oncol. 2010 Jun;19(2):55-8; discussion 61. doi: 10.1016/j.suronc.2010.01.004. Epub 2010 Feb 18.
5
Concepts in cancer survival analysis: research questions, data, and models.癌症生存分析的概念：研究问题、数据和模型。
Surg Oncol. 2010 Jun;19(2):52-4; discussion 61. doi: 10.1016/j.suronc.2010.03.003. Epub 2010 Apr 8.
6
Landmark analysis: A primer.地标分析：入门指南。
J Nucl Cardiol. 2019 Apr;26(2):391-393. doi: 10.1007/s12350-019-01624-z. Epub 2019 Feb 4.
7
A robust weighted Kaplan-Meier approach for data with dependent censoring using linear combinations of prognostic covariates.一种稳健的加权 Kaplan-Meier 方法，用于使用预后协变量的线性组合处理具有相依删失数据。
Stat Med. 2010 Sep 20;29(21):2215-23. doi: 10.1002/sim.3969.
8
Assessment of gastric cancer survival: using an artificial hierarchical neural network.胃癌生存率评估：使用人工分层神经网络
Pak J Biol Sci. 2008 Apr 15;11(8):1076-84. doi: 10.3923/pjbs.2008.1076.1084.
9
A semi-Markov multistate model for estimation of the mean quality-adjusted survival for non-progressive processes.一种用于估计非渐进性过程平均质量调整生存时间的半马尔可夫多状态模型。
Lifetime Data Anal. 2009 Jun;15(2):216-40. doi: 10.1007/s10985-008-9106-0. Epub 2008 Dec 10.
10
Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.个体患者数据荟萃分析中估计受限平均生存时间差异的方法的偏倚和精度。
BMC Med Res Methodol. 2016 Mar 29;16:37. doi: 10.1186/s12874-016-0137-z.
引用本文的文献
1
Effects of Antibiotic De-Escalation on Outcomes in Severe Community-Acquired Pneumonia: An Inverse Propensity Score-Weighted Analysis.抗生素降阶梯治疗对重症社区获得性肺炎预后的影响：一项逆概率加权分析
Antibiotics (Basel). 2025 Jul 17;14(7):716. doi: 10.3390/antibiotics14070716.
2
Importance of Surgical Margins in Patients with Early-Stage Merkel Cell Carcinoma.手术切缘在早期默克尔细胞癌患者中的重要性
Dermatol Ther (Heidelb). 2025 Mar;15(3):733-746. doi: 10.1007/s13555-025-01345-x. Epub 2025 Feb 23.
3
Cardiovascular Disease and Breast Cancer: Exploring 2 Interconnected Landscapes.心血管疾病与乳腺癌：探索两个相互关联的领域。
JACC CardioOncol. 2024 Dec 17;6(6):904-906. doi: 10.1016/j.jaccao.2024.10.008. eCollection 2024 Dec.
4
Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer.转移性乳腺癌女性患者 CDK4/6 抑制剂剂量降低后的总生存期
BJC Rep. 2024 Oct 21;2(1):82. doi: 10.1038/s44276-024-00108-z.
5
Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries.评估阿替利珠单抗治疗非小细胞肺癌患者的风险分担协议：一种改善低收入国家药物可及性的策略。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyae272.
6
Construction of a nomogram with IrAE and clinic character to predict the survival of advanced G/GEJ adenocarcinoma patients undergoing anti-PD-1 treatment.构建一个结合免疫相关不良反应（IrAE）和临床特征的列线图，以预测接受抗程序性死亡蛋白1（PD-1）治疗的晚期胃食管交界腺癌患者的生存期。
Front Immunol. 2024 Jul 24;15:1432281. doi: 10.3389/fimmu.2024.1432281. eCollection 2024.
7
Non-High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease Events.从儿童期到成年期的非高密度脂蛋白胆固醇水平与心血管疾病事件。
JAMA. 2024 Jun 4;331(21):1834-1844. doi: 10.1001/jama.2024.4819.
8
Profiling regulatory T lymphocytes within the tumor microenvironment of breast cancer via radiomics.通过放射组学对乳腺癌肿瘤微环境中的调节性 T 淋巴细胞进行分析。
Cancer Med. 2023 Dec;12(24):21861-21872. doi: 10.1002/cam4.6757. Epub 2023 Dec 11.
9
Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.识别预测性基因组生物标志物，以指导同步低容量转移性去势敏感前列腺癌的前列腺定向治疗。
Eur Urol Oncol. 2024 Apr;7(2):241-247. doi: 10.1016/j.euo.2023.07.014. Epub 2023 Aug 8.
本文引用的文献
1
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.前列腺特异性抗原最低点作为生存结局的独立预测因子：对 PROSPER 随机临床试验的事后分析。
J Urol. 2023 Mar;209(3):532-539. doi: 10.1097/JU.0000000000003084. Epub 2023 Feb 9.
2
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.对一线治疗产生完全缓解的转移性肾细胞癌患者的特征分析：国际转移性肾细胞癌数据库联盟的结果
J Urol. 2023 Apr;209(4):701-709. doi: 10.1097/JU.0000000000003132. Epub 2022 Dec 27.
3
Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach.基于里程碑法的前列腺低级别癌主动监测的长期随访结果：一项基于人群的研究
J Urol. 2023 Mar;209(3):540-548. doi: 10.1097/JU.0000000000003097. Epub 2022 Dec 7.
4
The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.细胞减积性肾切除术在转移性肾细胞癌中的作用：一项真实世界的多机构分析。
J Urol. 2022 Jul;208(1):71-79. doi: 10.1097/JU.0000000000002495. Epub 2022 Feb 25.
5
A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model.时变协变量在 Fine-Gray 亚分布风险竞争风险回归模型中的应用综述。
Stat Med. 2020 Jan 30;39(2):103-113. doi: 10.1002/sim.8399. Epub 2019 Oct 29.
6
Guidelines for Reporting of Statistics for Clinical Research in Urology.泌尿外科临床研究统计学报告的指南。
J Urol. 2019 Mar;201(3):595-604. doi: 10.1097/JU.0000000000000001.
7
Time-dependent covariates in the Cox proportional-hazards regression model.Cox比例风险回归模型中的时间相依协变量。
Annu Rev Public Health. 1999;20:145-57. doi: 10.1146/annurev.publhealth.20.1.145.
8
Analysis of survival by tumor response.根据肿瘤反应分析生存率。
J Clin Oncol. 1983 Nov;1(11):710-9. doi: 10.1200/JCO.1983.1.11.710.
Zotero 插件